Work

Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.11020

Authors: Yingmiao Liu, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Herbert Hurwitz, Andrew B. Nixon

Institutions: Duke Medical Center, Duke University, Tracon Pharmaceuticals (United States)

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601269790

Cites:

Cited by:

Related to: 10